Probing Remission in SLE: Blood and Brain (PRiSE)
Research type
Research Study
Full title
Probing Remission in SLE: Blood and Brain (PRiSE)
IRAS ID
298507
Contact name
David Isenberg
Contact email
Sponsor organisation
Feinstein Institutes for Medical Research
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
This is a prospective, observational study of SLE patients considered to be in clinical remission (SLE-R). In Project 1, Remission Immune Phenotypes, patients will be followed every 6 months for a maximum of 3 years. At each time point clinical information will be collected and blood will be drawn for research purposes. Comparison groups will be SLE patients with active disease (SLE-A) and healthy individuals (HC) that will have clinical information and blood collected only at baseline. All participants will have the option to collect additional stool and urine samples at baseline. SLE-R participants who choose to collect the stool and urine samples will additionally collect them annually and/or at time of disease flare. In Project 2, the Brain Function sub-Study, subgroups of SLE-R, SLE-A and HC will have brain assessments, including neuropsychological testing and brain imaging, completed at Baseline and then 18-24 months after baseline and/or at the time of a disease flare (if this occurs).
REC name
Wales REC 1
REC reference
23/WA/0345
Date of REC Opinion
23 Jan 2024
REC opinion
Further Information Favourable Opinion